Glofitamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and ≥2 Prior Therapies: Results From a Pivotal Phase II Expansion Study

被引：0

作者：

Dickinson, Michael ^{[1
,2
]}

Carlo-Stella, Carmelo ^{[3
,4
]}

Morschhauser, Franck ^{[5
,6
]}

Bachy, Emmanuel ^{[7
]}

Corradini, Paolo ^{[8
,9
]}

Iacoboni, Gloria ^{[10
]}

Khan, Cyrus ^{[11
]}

Wrobel, Thomasz ^{[12
]}

Offner, Fritz ^{[13
]}

Trneny, Marek ^{[14
]}

Wu, Shang-Ju ^{[15
]}

Cartron, Guillaume ^{[16
]}

Hertzberg, Mark ^{[17
,18
]}

Sureda, Anna ^{[19
]}

Perez-Callejo, David ^{[20
]}

Lundberg, Linda ^{[20
]}

Relf, James ^{[21
]}

Clark, Emma ^{[21
]}

Humphrey, Kathryn ^{[21
]}

Hutchings, Martin ^{[22
]}

机构：

[1] Royal Melbourne Hosp, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[2] Univ Melbourne, Melbourne, Vic, Australia

[3] Humanitas Univ, Milan, Italy

[4] IRCCS Humanitas Res Hosp, Milan, Italy

[5] Hop Claude Huriez, Lille, France

[6] CHU Lille, Lille, France

[7] Ctr Hosp Lyon Sud, Lyon, France

[8] Univ Milan, Milan, Italy

[9] IRCSS Ist Nazl Tumori, Fdn Ist Ricovero & Cura Carattere Sci, Milan, Italy

[10] Vall dHebron Univ Hosp, Barcelona, Spain

[11] Allegheny Hlth Network, Pittsburgh, PA USA

[12] Uniwersytet Med Wroclawiu, Wroclaw, Poland

[13] Univ Ziekenhuis Gent, Ghent, Belgium

[14] Charles Univ Hosp, Prague, Czech Republic

[15] Natl Taiwan Univ Hosp, Taipei, Taiwan

[16] CHU Montpellier, Montpellier, France

[17] Prince Wales Hosp, Sydney, NSW, Australia

[18] Univ New South Wales, Sydney, NSW, Australia

[19] Inst Catala Oncol Hosp, Barcelona, Spain

[20] F Hoffmann La Roche Ltd, Basel, Switzerland

[21] Roche Prod Ltd, Welwyn Garden City, Herts, England

[22] Rigshosp, Copenhagen, Denmark

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

ABCL; glofitamab; diffuse large B-cell lymphoma; bispecific antibody; relapsed/refractory; phase II;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ABCL-478

引用

页码：S435 / S435

页数：1

共 50 条

[41] A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Kalakonda, Nagesh
Cavallo, Federica
Follows, George
Goy, Andre
Vermaat, Joost S. P.
Casasnovas, Olivier
Lavee, Orly
Maerevoet, Marie
Zijlstra, Josee
Bakhshi, Sameer
Bouabdallah, Reda
Choquet, Sylvain
Gurion, Ronit
Hill, Brian
Jaeger, Ulrich
Sancho, Juan-Manuel
Schuster, Michael
Thieblemont, Catherine
De la Cruz, Fatima
Egyed, Miklos
Mishra, Sourav
Offner, Fritz
Vassilakopoulos, Theodoros
Warzocha, Krzysztof
McCarthy, Daniel
Ma, Xiwen
Corona, Kelly
Saint-Martin, Jean-Richard
Joshi, Anita
Shah, Jatin
Van den Neste, Eric
Canales, Miguel
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S248 - S249
[42] Salvage therapy for relapsed or refractory diffuse large B-cell lymphoma: impact of prior rituximab
Sud, Rohit
Friedberg, Jonathan W.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 (12): : 1776 - 1780
[43] Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma
Robertson, Michael J.
Kahl, Brad S.
Vose, Julie M.
de Vos, Sven
Laughlin, Mary
Flynn, Patrick J.
Rowland, Kendrith
Cruz, Jose C.
Goldberg, Stuart L.
Musib, Luna
Darstein, Christelle
Enas, Nathan
Kutok, Jeffery L.
Aster, Jon C.
Neuberg, Donna
Savage, Kerry J.
LaCasce, Ann
Thornton, Donald
Slapak, Christopher A.
Shipp, Margaret A.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) : 1741 - 1746
[44] Final results of a phase II trial of R-IDEA as salvage therapy in patients with relapsed/refractory diffuse large B-cell lymphoma
Kondo, E.
Yamamoto, K.
Masunari, T.
Takizawa, J.
Miura, K.
Masaki, Y.
Matsumura, T.
Hiramatsu, Y.
Murakam, J.
Tsujimura, H.
Tomita, N.
Maeda, Y.
Kanno, M.
ANNALS OF ONCOLOGY, 2016, 27
[45] Dual target dilemma: navigating epcoritamab vs. glofitamab in relapsed refractory diffuse large B-cell lymphoma
Davis, James A.
Granger, Katelynn
Sakowski, Alex
Goodwin, Sara
Herbst, Amanda
Smith, Deidra
Hendrickson, Lindsey
Nachar, Victoria R.
EXPERT REVIEW OF HEMATOLOGY, 2023, 16 (12) : 915 - 918
[46] Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study
Cartron, Guillaume
Houot, Roch
Al Tabaa, Yassine
Le Bras, Fabien
Ysebaert, Loic
Choquet, Sylvain
Jardin, Fabrice
Bay, Jacques-Olivier
Gros, Francois-Xavier
Morschhauser, Franck
Casasnovas, Olivier
Gastinne, Thomas
Thieblemont, Catherine
Joris, Magalie
Ricard, Laure
Regny, Caroline
La Rochelle, Laurianne Drieu
Feugier, Pierre
Marcais, Ambroise
Griolet, Samuel
Tarte, Karin
Laurent, Camille
Sesques, Pierre
NATURE CANCER, 2025,
[47] Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO
Martin Garcia-Sancho, A.
Baile, M.
Rodriguez, G.
Dlouhy, I.
Sancho, J. M.
Jarque, I.
Gonzalez-Barca, E.
Salar, A.
Espeso, M.
Grande, C.
Bergua, J.
Montes-Moreno, S.
Redondo, A.
Enjuanes, A.
Campo, E.
Lopez-Guillermo, A.
Caballero, D.
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 203 (02) : 202 - 211
[48] Subcutaneous Epcoritamab in Relapsed or Refractory Large B-Cell Lymphoma: Pivotal Results from the Phase 2 EPCORE NHL-1 Trial
Catherine, Thieblemont
Tycel, Phillips
Herve, Ghesquieres
Cheah, Chan Y.
David, Cunningham
Do, Young R.
Tatyana, Feldman
Robin, Gasiorowski Robin
Wojciech, Jurczak
Tae, Min Kim Tae M.
Lewis, David J.
Mariolein, Van der Poe
Poon, Michelle L.
Thomas, Doerr
Nurgul, Kilavuz
Menghui, Chen
Mariana, Sacchi
Martin, Hutchings
Pieternella, Lugtenburg
Roost, Clausen Michael
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S31 - S32
[49] A Phase 3 Study of Tafasitamab Plus Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)
Larsen, Thomas S.
Manzke, Oliver
Leibovitz, Daniel
Arbushites, Michael
BLOOD, 2022, 140 : 12077 - 12078
[50] A Phase 2 Trial of AZD1152 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Collins, Graham P.
Toby, Eyre A.
Hatton, Chris S.
Radford, John
Linton, Kim M.
BLOOD, 2014, 124 (21)

← 1 2 3 4 5 →